
Pubmed-entry ::= {
  pmid 29775310,
  medent {
    em std {
      year 2018,
      month 5,
      day 19,
      hour 6,
      minute 0
    },
    cit {
      title {
        name "Fragment-Based Discovery of a Potent, Orally Bioavailable
 Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2."
      },
      authors {
        names std {
          {
            name ml "Heightman TD",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Berdini V",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Braithwaite H",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Buck IM",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Cassidy M",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Castro J",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Courtin A",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Day JEH",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "East C",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Fazal L",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Graham B",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Griffiths-Jones CM",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Lyons JF",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Martins V",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Muench S",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Munck JM",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Norton D",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "O'Reilly M",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Palmer N",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Pathuri P",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Reader M",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Rees DC",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Rich SJ",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Richardson C",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Saini H",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Thompson NT",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Wallis NG",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Walton H",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Wilsher NE",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Woolford AJ",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          },
          {
            name ml "Cooke M",
            affil str "Sygnature Discovery Ltd., BioCity , Pennyfoot Street ,
 Nottingham , NG1 1GF , U.K."
          },
          {
            name ml "Cousin D",
            affil str "Sygnature Discovery Ltd., BioCity , Pennyfoot Street ,
 Nottingham , NG1 1GF , U.K."
          },
          {
            name ml "Onions S",
            affil str "Sygnature Discovery Ltd., BioCity , Pennyfoot Street ,
 Nottingham , NG1 1GF , U.K."
          },
          {
            name ml "Shannon J",
            affil str "Sygnature Discovery Ltd., BioCity , Pennyfoot Street ,
 Nottingham , NG1 1GF , U.K."
          },
          {
            name ml "Watts J",
            affil str "Sygnature Discovery Ltd., BioCity , Pennyfoot Street ,
 Nottingham , NG1 1GF , U.K."
          },
          {
            name ml "Murray CW",
            affil str "Astex Pharmaceuticals , 436 Cambridge Science Park ,
 Cambridge , CB4 0QA , U.K."
          }
        }
      },
      from journal {
        title {
          iso-jta "J. Med. Chem.",
          ml-jta "J Med Chem",
          issn "1520-4804",
          name "Journal of medicinal chemistry"
        },
        imp {
          date std {
            year 2018,
            month 6,
            day 14
          },
          volume "61",
          issue "11",
          pages "4978-4992",
          language "eng",
          pubstatus ppublish,
          history {
            {
              pubstatus pubmed,
              date std {
                year 2018,
                month 5,
                day 19,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus medline,
              date std {
                year 2019,
                month 5,
                day 21,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus other,
              date std {
                year 2018,
                month 5,
                day 19,
                hour 6,
                minute 0
              }
            }
          }
        }
      },
      ids {
        pubmed 29775310,
        doi "10.1021/acs.jmedchem.8b00421",
        other {
          db "ELocationID doi",
          tag str "10.1021/acs.jmedchem.8b00421"
        }
      }
    },
    abstract "Aberrant activation of the MAPK pathway drives cell
 proliferation in multiple cancers. Inhibitors of BRAF and MEK kinases are
 approved for the treatment of BRAF mutant melanoma, but resistance frequently
 emerges, often mediated by increased signaling through ERK1/2. Here, we
 describe the fragment-based generation of ERK1/2 inhibitors that block
 catalytic phosphorylation of downstream substrates such as RSK but also
 modulate phosphorylation of ERK1/2 by MEK without directly inhibiting MEK.
 X-ray crystallographic and biophysical fragment screening followed by
 structure-guided optimization and growth from the hinge into a pocket
 proximal to the C-alpha helix afforded highly potent ERK1/2 inhibitors with
 excellent kinome selectivity. In BRAF mutant cells, the lead compound
 suppresses pRSK and pERK levels and inhibits proliferation at low nanomolar
 concentrations. The lead exhibits tumor regression upon oral dosing in BRAF
 mutant xenograft models, providing a promising basis for further optimization
 toward clinical pERK1/2 modulating ERK1/2 inhibitors.",
    mesh {
      {
        term "Administration, Oral"
      },
      {
        term "Animals"
      },
      {
        term "Biocatalysis",
        qual {
          {
            mp TRUE,
            subh "drug effects"
          }
        }
      },
      {
        term "Biological Availability"
      },
      {
        term "Cell Line, Tumor"
      },
      {
        mp TRUE,
        term "Drug Discovery"
      },
      {
        term "Humans"
      },
      {
        term "Mice"
      },
      {
        term "Mitogen-Activated Protein Kinase 1",
        qual {
          {
            mp TRUE,
            subh "antagonists & inhibitors"
          },
          {
            subh "chemistry"
          },
          {
            mp TRUE,
            subh "metabolism"
          }
        }
      },
      {
        term "Mitogen-Activated Protein Kinase 3",
        qual {
          {
            mp TRUE,
            subh "antagonists & inhibitors"
          },
          {
            subh "chemistry"
          },
          {
            mp TRUE,
            subh "metabolism"
          }
        }
      },
      {
        term "Models, Molecular"
      },
      {
        term "Phosphorylation",
        qual {
          {
            subh "drug effects"
          }
        }
      },
      {
        term "Protein Conformation"
      },
      {
        term "Protein Kinase Inhibitors",
        qual {
          {
            subh "administration & dosage"
          },
          {
            subh "chemistry"
          },
          {
            subh "pharmacokinetics"
          },
          {
            mp TRUE,
            subh "pharmacology"
          }
        }
      }
    },
    substance {
      {
        type nameonly,
        name "Protein Kinase Inhibitors"
      },
      {
        type ec,
        cit "2.7.11.24",
        name "Mitogen-Activated Protein Kinase 1"
      },
      {
        type ec,
        cit "2.7.11.24",
        name "Mitogen-Activated Protein Kinase 3"
      }
    },
    pmid 29775310,
    pub-type {
      "Journal Article"
    },
    status medline
  }
}


